Loading clinical trials...
Loading clinical trials...
A Phase 1 First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR441000 Administered Intratumorally as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Conditions
Interventions
SAR441000
Cemiplimab REGN2810
Locations
19
United States
Dana-Farber Cancer Institute- Site Number : 8400003
Boston, Massachusetts, United States
Cleveland Clinic - Cleveland- Site Number : 8400007
Cleveland, Ohio, United States
The University of Texas MD Anderson Cancer Center- Site Number : 8400002
Houston, Texas, United States
Investigational Site Number : 0560001
Brussels, Belgium
Investigational Site Number : 0560003
Ghent, Belgium
Investigational Site Number : 0560002
Leuven, Belgium
Start Date
January 3, 2019
Primary Completion Date
July 25, 2022
Completion Date
February 21, 2024
Last Updated
September 10, 2025
NCT05103358
NCT01606033
NCT05943301
NCT02560311
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions